Effect of CVA21, an Oncolytic Virus, in combination with Pembrolizumab on immunogenicity and the tumour microenvironment in advanced NSCLC: a phase I/II trial.

已完结 20 由囡囡发布于 2025/12/17 16:25:28

DOI:10.1158/1078-0432.ccr-25-1449
作者：Adithya Balasubramanian,Claire Marceaux,Sehrish Kanwal,Ilariya Tarasova,Daniel Batey,Clare Senko,Khashayar Asadi,Kenta Yokote,Jodie Palmer,Michael Christie,Ashray Gunjur,Surein Arulananda,Sagun Parakh
文献类型：期刊论文
补充材料：只需要正文
文献链接：https://doi.org/10.1158/1078-0432.ccr-25-1449

American Association for Cancer Research (AACR)

Abstract：PURPOSE Acquired or de novo resistance to immune checkpoint inhibitors occurs in the majority of advanced non-small cell lung cancers (NSCLC). There is an unmet need to improve outcomes for

应助信息

求助已完结，文件已删除 如有需求请重新发布求助一键发布

感谢使用Book学术
本站所有文献仅供个人学习和参考，请勿将文件进行传播。共同遵守网站规定和相关知识产权规定。

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:其它数据库Enzymatic resolution of malonate diesters: A review of recent advances